Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED) | NCT00482638 | Trialant
CompletedInterventionalPhase 2Updated Nov 14, 2019
Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)
ClinicalTrials.gov ID
NCT00482638
Lead Sponsor
Merck Sharp & Dohme LLCINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Last Update Posted
Nov 14, 2019Actual
Start Date
May 12, 2004Actual
Primary Completion Date
Oct 29, 2004Actual
Completion Date
Oct 29, 2004Actual
Brief Summary
To assess the effect of MK0493 on body weight, blood pressure, mood, and appetite.
Obesity
MK0493
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is between 21 and 65 years
Patient is able to read and understand and complete study questionnaires
Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and post-study follow-up period
Exclusion Criteria:
Patient has a history of significant psychiatric disorder (such as major depression, bipolar disorder, bulimia, or anorexia nervosa
Patient is HIV positive as determined by medical history
Patient has undergone surgical treatment for obesity
Patient plans to consume more than two 8 ounce glasses of grapefruit juice per day during the study
Patient participated in another clinical study involving an investigational drug) within 3 months prior to Visit 1
Patient is currently a heavy consumer of alcohol (>2 drinks per day or >14 drinks per week [1 drink is defined as 2 oz hard alcohol, 5 oz wine, 12 oz beer], or uses (including recreational use) any illicit drugs, or has a history of drug or alcohol abuse